Abstract
Objective: To evaluate the possible effect of a single nucleotide polymorphism- 46698G>A, of 5-hydroxytryptamine type 3B (5-HT3B) receptor gene on anti-emetic efficacy of ondansetron in preventing post-operative nausea and vomiting (PONV).
Study Design: A prospective, clinical trial.
Place and Duration: Clinical data collection and blood sampling was carried out at Combined Military Hospital, Rawalpindi. Genetic analysis was carried out at Institute of Biomedical and Genetic Engineering, Islamabad from 01 Aug 2012 to 22 Sep 2013.
Methods: A single nucleotide polymorphism of 5-HT3B receptor gene, 46698G>A in 3’ near gene position was selected and genotyped in 368 Pakistani post-operative patients. These patients had undergone elective laparoscopic cholecystectomy and were given anti-emetic ondansetron 0.1 mg/kg half an hour before the end of surgery. 46698G>A was screened using Taqman assays. The relationship between genetic polymorphisms and clinical outcomes of ondansetron treatment was investigated.
Results: No significant association was found between the incidence of nausea and vomiting and the 46698G>A polymorphism of the 5-HT3B gene at 2 hours after surgery.
Conclusion: The 46698G>A variant of the 5-HT3B gene may affect PONV and predict the responsiveness to ondansetron.
Kulsoom Farhat , Akbar Waheed, Anwar Kamal Pasha. (2018) Impact of 46698g>A Polymorphism in the 5-Hydroxytryptamine Type 3b Receptor Gene on the Anti-Emetic Efficacy of Ondansetron, Isra Medical Journal, Volume 10, 01.
-
Views
869 -
Downloads
87
Article Details
Journal
Volume
Issue
Type
Language
Received At
Accepted At
